134 related articles for article (PubMed ID: 7549896)
41. Mutagenic properties of topoisomerase-targeted drugs.
Baguley BC; Ferguson LR
Biochim Biophys Acta; 1998 Oct; 1400(1-3):213-22. PubMed ID: 9748584
[TBL] [Abstract][Full Text] [Related]
42. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.
Capranico G; Binaschi M; Borgnetto ME; Zunino F; Palumbo M
Trends Pharmacol Sci; 1997 Sep; 18(9):323-9. PubMed ID: 9345851
[TBL] [Abstract][Full Text] [Related]
43. Molecular mechanisms of anthracycline activity.
Beretta GL; Zunino F
Top Curr Chem; 2008; 283():1-19. PubMed ID: 23605626
[TBL] [Abstract][Full Text] [Related]
44. The localization of topoisomerase II cleavage sites on DNA in the presence of antitumor drugs.
Paoletti C
Pharmacol Ther; 1993 Nov; 60(2):381-7. PubMed ID: 8022867
[TBL] [Abstract][Full Text] [Related]
45. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy.
Giles GI; Sharma RP
Med Chem; 2005 Jul; 1(4):383-94. PubMed ID: 16789895
[TBL] [Abstract][Full Text] [Related]
46. Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex.
Palumbo M; Gatto B; Moro S; Sissi C; Zagotto G
Biochim Biophys Acta; 2002 Jul; 1587(2-3):145-54. PubMed ID: 12084456
[TBL] [Abstract][Full Text] [Related]
47. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
Holden JA
Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
[TBL] [Abstract][Full Text] [Related]
48. Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics.
Fujii N; Yamashita Y; Mizukami T; Nakano H
Mol Pharmacol; 1997 Feb; 51(2):269-76. PubMed ID: 9203632
[TBL] [Abstract][Full Text] [Related]
49. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
Larsen AK; Gobert C
Pathol Oncol Res; 1999; 5(3):171-8. PubMed ID: 10491013
[TBL] [Abstract][Full Text] [Related]
50. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Larsen AK; Skladanowski A
Biochim Biophys Acta; 1998 Oct; 1400(1-3):257-74. PubMed ID: 9748618
[TBL] [Abstract][Full Text] [Related]
51. The mapping of DNA topoisomerase sites in vivo: a tool to enlight the functions of topoisomerases.
Borde V; Duguet M
Biochimie; 1998 Mar; 80(3):223-33. PubMed ID: 9615862
[TBL] [Abstract][Full Text] [Related]
52. Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges.
Capranico G; Zagotto G; Palumbo M
Curr Med Chem Anticancer Agents; 2004 Jul; 4(4):335-45. PubMed ID: 15281906
[TBL] [Abstract][Full Text] [Related]
53. A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons).
Jenkins JR
Br J Radiol; 2008 Oct; 81 Spec No 1():S69-77. PubMed ID: 18820001
[TBL] [Abstract][Full Text] [Related]
54. Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes.
Hong G; Kreuzer KN
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5046-51. PubMed ID: 12704241
[TBL] [Abstract][Full Text] [Related]
55. Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors.
Beretta GL; Perego P; Zunino F
Expert Opin Ther Targets; 2008 Oct; 12(10):1243-56. PubMed ID: 18781823
[TBL] [Abstract][Full Text] [Related]
56. Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents.
Yakkala PA; Penumallu NR; Shafi S; Kamal A
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895927
[TBL] [Abstract][Full Text] [Related]
57. [DNA topoisomerase and telomerase activity with relation to multi-drug resistance in leukemia--review].
Li SJ; Gu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):207-10. PubMed ID: 17490556
[TBL] [Abstract][Full Text] [Related]
58. Topoisomerase IB: a relaxing enzyme for stressed DNA.
Soren BC; Dasari JB; Ottaviani A; Iacovelli F; Fiorani P
Cancer Drug Resist; 2020; 3(1):18-25. PubMed ID: 35582040
[TBL] [Abstract][Full Text] [Related]
59. Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.
Jain CK; Majumder HK; Roychoudhury S
Curr Genomics; 2017 Feb; 18(1):75-92. PubMed ID: 28503091
[TBL] [Abstract][Full Text] [Related]
60. Leukaemogenesis: a postulated mechanism involving tyrosine protein kinase and DNA topoisomerase.
Francis GE
Med Hypotheses; 1987 Feb; 22(2):195-207. PubMed ID: 3033453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
